In addition, the TME, TMB, MSI, and immune infiltration might contribute to the dysregulation of CHD5 expression in cancer, and CHD5 may be a potential therapeutic target for glioma immunotherapy. The gene discussed is CHD5; the disease is central nervous system cancer.